Since its identification in 1997, myostatin has been considered as a novel and unique
negative regulator of muscle growth, as mstn−/− mice display a dramatic and widespread …

By using a conditional gene targeting approach exploiting the cre‐lox system, we show that
postnatal inactivation of the myostatin gene in striated muscle is sufficient to cause a …

Myostatin (MSTN) is a transforming growth factor-β family member that plays a critical role in
regulating skeletal muscle mass. Genetic studies in multiple species have demonstrated that …

Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …

In addition to gene correction therapy and cell transplantation techniques, multidisciplinary
approaches to drug discovery and development offer promising therapeutic strategies for …

Obesity and insulin resistance cause serious consequences to human health. To study
effects of skeletal muscle growth on obesity prevention, we focused on a key gene of …

Inhibitors of myostatin, a negative regulator of skeletal muscle mass, are being developed to
mitigate aging‐related muscle loss. Knock‐out (KO) mouse studies suggest myostatin also …

Myostatin is a member of the transforming growth factor (TGF)-β superfamily. It is expressed
by animal and human skeletal muscle cells where it limits muscle growth and promotes …

Skeletal muscle fibrosis is a major pathological hallmark of chronic myopathies in which
myofibers are replaced by progressive deposition of collagen and other extracellular matrix …

Sarcopenia is the progressive loss of skeletal muscle mass and function with advancing
age, leading to reduced mobility and quality of life. We tested the hypothesis that antibody …